APT 3111
Alternative Names: APT 2392; CD59-ProdaptinLatest Information Update: 02 Aug 2005
At a glance
- Originator Inflazyme Pharmaceuticals
- Class
- Mechanism of Action CD59 antigen agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 30 Apr 2005 Discontinued - Preclinical for Paroxysmal nocturnal haemoglobinuria in United Kingdom (unspecified route)
- 21 Apr 2004 Adprotech has been acquired by Inflazyme Pharmaceuticals
- 19 May 2003 APT 3111 has received orphan drug status for paroxysmal nocturnal haemoglobinuria in United Kingdom